Q4 2024 Management View CEO Tim Herbert highlighted milestones in 2024, including surpassing 90,000 patients treated with Inspire therapy, FDA approval of the Inspire V neurostimulator, and achieving full-body MRI compatibility in the European Union.

MINNEAPOLIS, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter and year ended December 31, 2024.

RBC Capital Markets upheld a positive outlook on Inspire Medical Systems (NYSE:INSP) shares, reiterating an Outperform rating with a steady price target of $260.00. The stock currently trades at $180.

Inspire Medical Systems, Inc. ( NYSE: INSP) Q4 2024 Earnings Conference Call February 10, 2025 5:00 PM ET Ezgi Yagci - Vice President of Investor Relations Tim Herbert - President & Chief Executive Officer Rick Buchholz - Chief Financial Officer

Truist lowered the firm’s price target on Inspire Medical (INSP) to $235 from $250 and keeps a Buy rating on the shares. The company’s Q4